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an unclassified cystinuria, although the clinical characterizationCystinuria in children: Distribution and frequencies of muta-
in the first group was more stringent; additionally, differenttions in the SLC3A1 and SLC7A9 genes.
spectrums of mutations were observed. The lack of detectableBackground. Cystinuria is a common inherited disorder of
mutations in many patients indicates the possibility of otherdefective renal reabsorption of cystine, ornithine, lysine and
yet unidentified genes involved in cystinuria. We could notarginine leading to nephrolithiasis. Two responsible genes have
correlate the severity of the disease to the type of cystinuriabeen identified so far: Mutations in the SLC3A1 gene encoding
in the pediatric patients.the heavy chain rbAT of the renal cystine transport system
rbAT/b0,AT cause cystinuria type I, while variants in SLC7A9,
the gene of its light chain b0,AT, have been demonstrated in
non-type I cystinuria. In this study, we searched for mutations
Cystinuria is a heritable disorder of amino acid trans-in both genes in a cohort of children with cystinuria.
port in epithelial cells of the renal proximal tubule andMethods. Twenty-one cystinuric children from 16 families
were analyzed by mutational analysis of the genes SLC3A1 of the intestine. It is characterized by the urinary hyper-
and the SLC7A9. The patients were classified by the urinary excretion of cystine and the dibasic amino acids lysine,
amino acid excretion profile of their parents. Additionally, 10 ornithine and arginine; the underlying cause of the dis-unclassified patients were screened for genomic variants. The
ease is the defect in reabsorption across the brush borderscreening techniques included single strand conformation poly-
membrane of the epithelial cells of the renal tubule andmorphism analysis, restriction assays and direct sequencing.
Results. Two novel mutations were identified in SLC3A1 intestinal tract. Due to its low solubility, cystine precipi-
and three in SLC7A9; three were missense mutations and two tates in the distal tubule to form cystine stones that
frameshift mutations. In the pediatric patients, mutations were represent approximately 1 to 2% of all urinary nephroli-found in 54% of type I (SLC3A1) and in 25% of non-type I
thiasis in adults and 4 to 5% in children [1].(SLC7A9) chromosomes. For this group of patients a total
All pathological consequences including infections,detection rate of 46.6% for mutations in both genes was deline-
ated. In the cohort of unclassified 10 patients, 70% of mutations pyelonephritis, obstructive uropathy, and renal insuffi-
were determined. M467T and G105R were the preponderant ciency of cystinuria are caused by the recurrent urolithi-
mutations in SLC3A1 and SLC7A9, respectively; T216M was asis. The intestinal defect in the absorption of cystinethe major mutation in Turkey and Greece.
and dibasic amino acids has no practical consequences.Conclusions. The detection rate for mutations in SLC3A1
Two different types of cystinuria can be distinguishedand SLC7A9 in children was 54% in the SLC3A1 gene for
type I chromosomes and 25% in the SLC7A9 gene for non-type I based on the urinary cystine concentration pattern of
chromosomes. It was lower than that in 10 further patients with obligate heterozygotes and on their mode of inheritance:
Type I follows an autosomal recessive trait, and hetero-
zygotes show a normal aminoaciduria. In contrast, non-1 Members: H. Bachmann, A. Bo¨kenkamp, M. Fischbach, S. Fru¨nd,
K.G. Pistor, and H.F. Zappel. type I heterozygotes exhibit moderate or high excretion
of cystine and the dibasic amino acids; therefore, an
Key words: nephrolithiasis, pediatric cystinuria, defective renal reab-
autosomal dominant inheritance with incomplete pene-sorption, heredity, amino acid transport, hyperexcretion of cystine,
renal stone formation. trance can be defined for this type of cystinuria. The homo-
zygous patients (type I/type I, non-type I/non-type I) andReceived for publication December 7, 2001
mixed heterozygous patients (type I/non-type I) show aand in revised form May 3, 2002
Accepted for publication May 6, 2002 similar range of cystine hyperexcretion independent of
the disease type. 2002 by the International Society of Nephrology
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To date, two cystinuria genes have been identified [2, 3]: Classification of probands
the SLC3A1 gene (2p16.3) encodes the heavy chain The renal transport defect in the pediatric patients
rbAT of a renal cystine and dibasic amino acid trans- and their parents was assessed by urinary amino acid
porter, and the SLC7A9 gene (19q13.1) encodes the light excretion and percentage tubular amino acid reabsorp-
chain b0,AT. Whereas mutations in the SLC3A1 gene tion (%Taa). The pediatric probands were classified ac-
cause type I cystinuria, patients with non-type I cystinu- cording to the renal amino acid excretion in their parents
ria harbor mutations in the SLC7A9 gene. as described previously [5].
Until now it has been assumed that type I patients To avoid bacterial breakdown of amino acids, urine
show a more severe phenotype with earlier manifestation samples were passed through a sterile filter (0.2 m pore
than non-type I patients. Goodyer et al demonstrated size) and immediately stored at 20C. Blood samples
that type I/type I patients form stones in their first decade were deproteinized within 30 minutes after collection to
of life, while patients homozygous for non-type I or prevent cystine from binding to plasma protein. Amino
mixed heterozygotes only show increased urinary cystine acids were determined by ion exchange chromatography
values at this age [4]. on a Biotronic amino acid analyzer LC3000. Creatinine
To estimate the proportion by which mutations in was determined by a kinetic Jaffe´ reaction. Urinary
SLC3A1 and SLC7A9 contribute to early manifesting amino acids were corrected per gram of creatinine. The
forms of cystinuria, we screened 21 patients who were determination of %Taa was performed with creatinine as
seen at the different contributing centers of pediatric marker of glomerular filtration rate as described pre-
nephrology. Patients were classified by the urinary cys- viously [5].
tine excretion of their relatives. In addition, 10 unclassi-
fied cystinuric patients referred to urological clinics were DNA analysis
examined. Apart from determining the detection rate of Genomic DNA was isolated from peripheral lympho-
mutations in these two genes, we looked for the distribu- cytes by a salting-out procedure [6]. The whole coding
tion of the mutations in the two patients group; further-
region and the intron-exon boundaries of the SLC3A1
more, we tested for the correlation between phenotype
and SLC7A9 genes were screened for variations in geno-and genotype.
mic DNA by single strand conformation polymorphism
analysis (SSCP) in all patients. Fragments sizes were up
METHODS to 250 bp at maximum. Primer sequences for SLC3A1
were taken from the literature [2, 7–9]. The InternationalPatients
Cystinuria Consortium kindly provided information onTwenty-one cystinuric children from 16 families were
primers in the SLC7A9 gene. In case of exons 2, 4, andexamined. The patients were classified in cystinuria sub-
12, SSCP analysis was carried out by investigating twotypes on the basis of urinary excretion values of cystine
overlapping fragments. Details on these primers as welland dibasic amino acids in spontaneous urine specimens
as polymerase chain reaction (PCR) conditions may beof their direct relatives according to Langen et al [5].
obtained directly from the authors. PCR was carried outA summary of the phenotypes of the cystinuric chil-
in a 25 L volume, containing 80 ng genomic DNA, 50dren included in this study is given in Table 1. The major-
pmol of each primer, 50 mmol/L KCl, 10 mmol/L Tris-ity of families were of German or Turkish origin. All
HCl pH 8.3, 1.5 mmol/L MgCl2, 0.01% gelatin, 200mol/Lbut five patients showed stone formation, the age of first
of each deoxynucleoside triphosphate (dNTP), and 1 Umanifestation ranged from 9 months to 14 years. One
Taq Polymerase (Gibco BRL, Eggenstein, Germany).family with increased urinary cystine excretion but with-
For SSCP analysis, 5 L of the PCR product wereout stone formation yet was identified by a neonatal
mixed with 5 L of denaturing solution containing 80%neuroblastoma screening program (Cys 84/85). Another
deionized formamide, 0.0125% bromophenol blue, andpatient and her brother (Cys 93/94) were recruited due
0.75% Ficoll 400 and denatured for five minutes at 94C.to an increased cystine excretion diagnosed in the con-
Samples were subsequently chilled on ice and thentext of a metabolic analysis. Neither child has shown
loaded on a 10% polyacrylmide gel (acrylamide/bisacryl-stone formation so far.
amide  49:1; 110  120  1.0 mm, Multigel-Long/Bio-Additionally, 10 patients with a history of recurrent
metra) with and without 5% glycerol, containing 0.5 cystine kidney stones and elevated urine cystine level
Tris-buffered eosin (TBE). Gels were allowed to run forwere included in this study (Table 2). The composition
16 to 18 hours at 7 V/cm, both at room temperatureof stones was determined by radiation diffactrometry;
and at 4C. Bands were detected by silver staining. Torelatives could not be recruited, so these patients re-
enhance the sensitivity of SSCP, all PCR fragments weremained unclassified.
electrophoresed under four conditions: at 4C and atThe appropriate informed consent was obtained from
all patients and their relatives. room temperature, with and without glycerol. Neverthe-
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less, there remains the possibility that we have missed a patients were classified as follows: four patients were
homozygous for type I cystinuria, two showed homozy-mutation by relying on SSCP as a single mutation screen-
ing method. gosity for non-type I cystinuria, and amino acid excretion
in a further two cases revealed heterozygosity for non-Unusual SSCP or restriction patterns were character-
ized by direct sequencing of PCR products using the type I cystinuria (Table 1). The latter (Cys 84/85, Cys
93/94) were identified by a neuroblastoma screening pro-BigDyeTerminationCycleSequencingSystem (ABI, Fos-
ter City, CA, USA). Due to the presence of several gram and a metabolic analysis, respectively. Since single
paternal blood and urinary samples were not available,polymorphisms and mutations in exon 4 of SLC7A9,
interpretation of SSCP data patterns was impossible. only one cystinuria chromosome could be typed in five
patients, in three further patients specimens of both par-Therefore, this exon was sequenced in all patients.
Additionally, PCR-based restriction fragment length ents were not available. Therefore, 11 of the 30 cystinuria
chromosomes were type I, 8 non-type I, and 11 werepolymorphism assays for the known variants T216M,
S217R, R270X, R270L, L346P, R362C, R365W, R365L, unclassified (type I or non-type I). The age of first stone
formation in the affected children ranged from 9 monthsS547W, M467T, M467K, E483X, c.15001GT in
SLC3A1 as well as G105R, T123M, F140S, A182T, to 14 years. Eight of the 16 patients with stone formation
have not developed additional stones, 4 have sufferedc.747delG, E244 and R333W in SLC7A9 were used to
confirm the results obtained by SSCP. Analyses were from less than 5 recurrent stones, three from more than
5 stones. In patients without recurrent stone formation,performed as described previously [2, 3, 7, 8, 10–12].
In the case of the new mutations P508A in SLC3A1 the difference between first stone formation and last
examination was at least one year.and A331V in SLC7A9, we established restriction assays
as listed in Table 3. In the group of unclassified patients (N  10), the age
of first stone manifestation ranged from 6 to 24 years.
All 10 patients were ascertained due to recurrent kidney
RESULTS
stone formation.
In this study, 21 children with cystinuria from 16 fami- The whole coding regions and all intron/exon bound-
lies were investigated. The patients were classified ac- aries of the SLC3A1 and the SLC7A9 genes were investi-
cording to the renal amino acid excretion of their parents. gated in the cystinuric children and 10 unclassified pa-
Following the classification of urinary amino acid excre- tients. In case of patients showing apparent homozygosity,
tion published by Langen et al [5], the patients and their we could not distinguish between homozygosity and
parents were typed as follows (Table 1): type I homozy- hemizygosity, since only small fragments with SSCP and
gotes (I/I), non-type I homozygotes (non-I/non-I), mixed restriction assays were analyzed; large deletions as de-
heterozygotes (I/non-I) as well as patients with classical scribed for SLC3A1, spanning more than one exon, could
cystinuria, but only one parent available for classification not be detected. However, both situations revealed two
(I/unclassified or non-I/unclassified) excreted the af- mutations in the same gene, either homozygosity for
fected amino acids in similar amounts with very high the same mutation or compound heterozygosity for the
excretion rates of cystine (1.00 to 4.49 mmol/g creati- mutation and a deletion including the respective exon.
nine), ornithine (1.10 to 3.96 mmol/g creatinine), lysine In total, two novel mutations were identified in SLC3A1
(4.57 to 16.71 mmol/g creatinine) and arginine (0.89 to and three in SLC7A9 (Tables 1 to 3). Three were mis-
1.43 mmol/g creatinine). The obligate type I heterozy- sense mutations and were not found in 50 healthy con-
gotes showed normal excretion of cystine, ornithine, ly- trols. Additionally we identified one new frame shift
sine and arginine, while non-type I heterozygotes showed mutation in each gene.
intermediate values (Table 1).
Missense mutationsIn case of one family (Cys 77), the classification of the
mother was ambiguous due to a mild general hyperami- In the SLC3A1 gene, a C to G transition at cDNA
noaciduria of unknown origin. position 1523 (exon 9) leading to a substitution from
The classification was confirmed by the patterns of proline to alanine at position 508 (P508A) was detected
tubular amino acid reabsorption (data not shown): in in heterozygous state in a German patient (Cys 65).
the cystinuric patients (I/I, non-I/non-I, I/unclassified, In SLC7A9, a C to T substitution at nucleotide c.856
non-I/unclassified) %Taa was severely reduced for cystine (exon 6), which changed an alanine codon to a valine
and the dibasic amino acids; in non-type I heterozygotes codon at position 224 (A224V), was identified in a het-
%Taa was moderately reduced for cystine and lysine, erozygous state in two German sibs (Cys 93/94).
while ornithine and arginine were reabsorbed normally. A Turkish patient (Cys 70) showed homo- or hemizy-
Type I heterozygotes removed cystine and dibasic amino gosity for the amino acid substitution A331V, caused by
acids nearly completely from the tubular lumen. a C to T transition at nucleotide c.1177 in exon 10.
To allow rapid genotyping in the future, we developedBased on these biochemical criteria, the 16 unrelated
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Table 2. Summary of mutations in the 10 unclassified patients
Age at first Age at
stone formation examination
Number of Mutations in Mutations in
Patient years recurrent stones Ethnic origin SLC3A1 SLC7A9
Cys 48 16 52 10 German M467T/ —
Cys 49 18 34 5–10 German R270X/M467T —
Cys 50 11 30 10 German — G105R/
Cys 51 14 42 10 German — c.969_971dela
Cys 53 6 9 — Israel R270X/R270X —
Cys 65 21 43 10 German P508A/ —
Cys 88 23 37 10 German M467T/ —
Cys 89 16 40 	5 Russian — —
Cys 95 15 35 10 German M467T/R365W —
Cys 102 24 47 10 German R365W/R362C —
a Homo- or hemizygosity can not be differentiated
Table 3. Description of new mutations identified in the SLC3A1 and the SLC7A9 genes, primers for amplification and strategies for
mutation detection
Restriction site
Effect on Frequency Frequency
Gene Exon/intron Genomic variant coding region in patientsa in controls Created Destroyed Primers (5
→3
)
SLC3A1 Exon 9 c.1523CG P508A 1/56 0/50 BsmI SLC3A1-9F ctgttttccctttctggt
SLC3A1-9R tcatttgtttctagaatcaacata
Exon 10 c.1766_1768del Frame shift 1/56 — — SLC3A1-10F ggatcgagtgttttgggtaaat
SLC3A1-10.1R tcttattttagcgggaaggcc
SLC7A9 Exon 6 c.856CT A224V 1/56 0/50 — SLC7A9-6F tcccgtggagatacactcaagat
SLC7A9-ER tggagttaaagtcacctggagb
Exon 8 c.969_971 Frame shift 1/56 — — SLC7A9-BF2 ctgcctttggccattatcctcb
SLC7A9-BR1 acctccagtgctgacacctgb
Exon 10 c.1177CT A331V 1/256 0/50 AciI SLC7A9-HF ggagcacaagtcctcagtggb
SLC7A9-10R gccttgaagataggctggtag
a Including all patients, those published here as well as those published by Schmidt et al [12]
b Primer information was kindly provided by the International Cystinuria Consortium
PCR-based restriction assays for two of these mutations each in children, and R362C in an unclassified patient.
(Table 3). G105R in SLC7A9 was detected in two children and in
one unclassified patient.
Frame shift mutations Combining these mutations and the new variants, we
In the SLC3A1 gene, we identified a deletion in exon characterized 12 chromosomes in the pediatric patients
10 at position c.1767, resulting in a frame shift mutation (30 chromosomes). In detail, mutations in SLC3A1 were
(c.1749_1751del). The German patient (Cys 109) was characterized in 54% of the type I chromosomes in chil-
heterozygous for this genomic variation. In an unclassi- dren (6 of 11), and in the case of SLC7A9 25% of the
fied German cystinuric patient, homo/hemizygosity for non-type I chromosomes (2 of 8) were identified. The
a deletion in exon 8 of the SLC7A9 gene (c.969_971del) combined detection rate was 42.1%. In the remaining 11
was found. unclassified chromosomes, four mutations were detected
Furthermore, a possible splice site mutation was de- in SLC7A9 and two in SLC3A1. An overall detection
tected in one child of a German sibship (Cys 107): A de- rate of 46.6% (14 of 30 chromosomes) for mutations in
letion at nucleotide IVS62T (splice site exon 6/intron 6) both genes was delineated in all of our pediatric patients.
or IVS63T in SLC3A1 was found in heterozygous state. In the 10 unclassified patients, we detected 70% of
In addition to the identification of new mutations, six mutations (14 of 20 chromosomes) in SLC3A1 and
previously described mutations in SLC3A1 and one in SLC7A9: 55% showed mutations in SLC3A1 (11 of 20),
SLC7A9 were detected (Tables 1 and 2). Out of these, 15% in SLC7A9 (3 of 20).
the mutation M467T in SLC3A1 was the most frequent
one found, as it was identified in two of the children and
DISCUSSIONfour of the unclassified patients. The mutations R365W
In our study, 21 cystinuric children from 16 familiesand R270X in SLC3A1 were detected twice each in the
unclassified patients, T216M and S547W were found once as well as 10 unclassified patients were screened for geno-
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mic variants in the coding regions of the SLC3A1 and In the gene SLC7A9, G105R has been established as
the most frequent mutation (Tables 1 and 2) [3, 11].the SLC7A9 genes. We identified two and three novel
mutations in each gene, respectively. For SLC3A1, the Here, it was detected in a German and an Italian child
suffering from cystinuria, and in two of the unclassifiednumber of mutations described to date increases to 64,
and for SLC7A9 the number increases to 39 [reviewed patients.
In the unclassified patients including those 18 pub-in 10, 11, 13]. Two of the new mutations are frame shift
mutations, and the others are missense mutations. lished previously [12], 62.5% of mutations in SLC3A1
and SLC7A9 were detected: 50% showed mutations inThe two new mutations in SLC3A1 (P508A, c.1766_
1768del) are localized within the glycosidase-like extra- SLC3A1, 12.5% in SLC7A9. This result in an ethnically
mixed population agrees with a study in 27 untypedcellular domain of the protein. The variant c.1749_1751del
leads to a truncation of the C-terminus of the protein, North American patients in which mutations in SLC3A1
and SLC7A9 could be detected only in 56% of chromo-which is thought to be necessary for interaction with the
light subunit b0,AT and may affect transport properties somes.
Interestingly, the mutation detection rate of 46.6% inof the transporter complex [13]. The effect of the mis-
sense mutations on transport properties cannot be pre- the classified cystinuric children is lower than that of
the aforementioned 62.5% in the unclassified patients,dicted based on the current knowledge for the rbAT
protein structure. Most mutations described and ana- although the first group is defined more precisely. In
particular, we could explain only 25% of non-type Ilyzed in this region, however, affect trafficking of the
rbAT protein in the membrane (A. Albers et al, personal cystinuria chromosomes by mutations in SLC7A9, which
differs from a detection rate of 79% in non-type I chro-communication) [13]. Patients carrying these SLC3A1
mutations show a classical cystinuria, as described for mosomes published by the International Cystinuria Con-
sortium [11]. In 16 pediatric patients, four thus far un-all patients homozygous or compound heterozygous for
mutations in this gene. known mutations, two in the SLC3A1 gene and two in
the SLC7A9 gene, have been detected (Table 1). In theHeterozygosity for A224V in SLC7A9 was detected
in a German sibship (Cys 93/94). The mutation is local- cohort consisting of 10 unclassified patients (Table 2),
one new mutation in SLC3A1 and three in SLC7A9 wereized in a highly conserved transmembrane stretch of the
b0,AT subunit. The mutation A331V in SLC7A9 is lo- identified. While the search for mutations in SLC7A9 is
just beginning, the spectrum of mutations in SLC3A1 iscalized in an intracellular loop. It was detected in a Turk-
ish child whose heterozygous mother also shows a mod- well established. Thus, it can be hypothesized that children
with cystinuria, that is, early manifestation, show in parterate increase of cystine excretion; since we could not
distinguish between homo- or hemizygosity of A331V a different spectrum of mutations from those patients with
late-onset. Since we screened the whole coding regionin our patient, we cannot estimate whether homozygosity
of this mutation leads to a severe abnormal excretion by SSCP, these undetected mutations should be localized
in genomic regions not analyzed so far or should consistpattern or whether this pattern is caused by a putative
deletion. of large deletions that are not detectable with the meth-
ods used here. Additionally, further factors/genes seemThe deletion c.969_971del in exon 8 causes the frame
shift mutation L262fsX263 with a premature stop codon to be responsible for the disease in children.
Furthermore, the fact that the detection rates for mu-after position 295.
Moreover, we analyzed the distribution of frequencies tations in the two cystinuria genes published by different
groups never reach 100% as well as immunohistologicalof mutations detected in our patients and described in
the literature. M467T in SLC3A1 has been described as investigations [14] strongly suggest that other genes en-
coding subunits for renal amino acids transporters maythe most preponderant mutation in German and South-
west European patients: in our pediatric patients, it ac- exist and may carry mutations [11]. Indeed, Leclerc et
al suggested recently that mutations in the asc light chaincounted for 2 of 11 type I chromosomes, in unclassified
patients it was detectable in 9 of 56 cystinuria chromo- subunit (SLC7A10) also could be responsible for cystinu-
ria non-type I [15]. This gene is localized in 19q13, closesomes, including those published previously by Schmidt
et al (Tables 1 and 2) [12]. Three other mutated alleles to SLC7A9. However, it is thought that the asc trans-
porter is expressed basolaterally in polarized epitheliaalso were detected more than once (T216M, R270X,
R365W), out of which T216M seems to be preponderant such as the proximal tubule or small intestine and inter-
acts with the heavy chain 4F2hc [reviewed in 13]. There-in Greece [9] and Turkey. The mutation R270X was de-
tected in a German patient as well as in homo-/hemizygous fore, it is not clear at present whether SLC7A10 repre-
sents a third cystinuria gene.status in an Israeli. All other mutations in SLC3A1 were
detected only once. Thus, in good agreement with the Variability of age at first stone formation between sibs
with the same genotype was observed in some of ourliterature, it can be assumed that mutations in SLC3A1
are private or population specific. patients (Cys 63/64, Cys9/13 in [12]). Of course, whether
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